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Pleckstrin homology domain–containing, family H (with
MyTH4 domain), member 2 (Plekhh2) is a 1491-residue
intracellular protein highly enriched in renal glomerular
podocytes for which no function has been ascribed. Analysis
of renal biopsies from patients with focal segmental
glomerulosclerosis revealed a significant reduction in total
podocyte Plekhh2 expression compared to controls.
Sequence analysis indicated a putative a-helical coiled-coil
segment as the only recognizable domain within the
N-terminal half of the polypeptide, while the C-terminal half
contains two PH, a MyTH4, and a FERM domain. We identified
a phosphatidylinositol-3-phosphate consensus-binding site
in the PH1 domain required for Plekhh2 localization to
peripheral regions of cell lamellipodia. The N-terminal half of
Plekkh2 is not necessary for lamellipodial targeting but
mediates self-association. Yeast two-hybrid screening
showed that Plekhh2 directly interacts through its FERM
domain with the focal adhesion protein Hic-5 and actin.
Plekhh2 and Hic-5 coprecipitated and colocalized at the soles
of podocyte foot processes in situ and Hic-5 partially
relocated from focal adhesions to lamellipodia in Plekhh2-
expressing podocytes. In addition, Plekhh2 stabilizes the
cortical actin cytoskeleton by attenuating actin
depolymerization. Our findings suggest a structural
and functional role for Plekhh2 in the podocyte foot
processes.
Kidney International (2012) 82, 1071–1083; doi:10.1038/ki.2012.252;
published online 25 July 2012
KEYWORDS: cell biology and structure; cell–matrix interactions; cytoskeleton;
podocyte; protein interaction
The kidney glomerulus is a micro-organ comprising a
molecular filtration barrier that prevents the loss of blood
proteins into the primary filtrate. The capacity of the
glomerular filtration barrier to facilitate this function is
dependent on the coordinated function of its three constituent
layers: the endothelium, the glomerular basement membrane
(GBM), and the podocytes. Although each of the three layers
contributes to the permselectivity of the glomerular filtration
barrier, the podocyte forms the final barrier to filtration. As
such, the podocyte is critically positioned to determine the
ultimate composition of the primary urine that passes into
Bowman’s space.1 The essential role of the podocyte in
preventing the filtration of large blood proteins, such as
albumin, across the glomerular filtration barrier is provided by
genetic studies identifying podocyte genes that, when mutated,
result in podocyte dysfunction and nephrotic syndrome.2
Focal segmental glomerulosclerosis (FSGS) is one of the most
common causes of nephrotic syndrome among adults and is a
significant cause of chronic renal failure. It consists of several
different categories based on histological features, and recent
studies have identified a number of mutations in podocyte-
expressed genes that cause podocyte dysfunction and result in
some of the hereditary forms of FSGS.
The cytoarchitecture of the glomerular podocyte is
defined by three parts: the cell body, the major processes,
and the interdigitating foot processes. The foot processes of
individual podocytes enwrap the capillary and are inter-
connected with each other via specialized cell junctions, the
slit diaphragms,3 whereas their basal domains sit on the
GBM. Formation of this highly articulated morphology is
stringently dependent on the actomyosin cytoskeleton.
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2012 International Society of Nephrology
Received 20 December 2011; revised 4 April 2012; accepted 10 May
2012; published online 25 July 2012
Correspondence: Karl Tryggvason, Division of Matrix Biology, Department
of Medical Biochemistry and Biophysics, Karolinska Institutet, Scheeles va¨g 2,
Stockholm 171 77, Sweden. E-mail: karl.tryggvason@ki.se
7These authors contributed equally to this work.
Kidney International (2012) 82, 1071–1083 1071
The actin filament network is the predominant cytoskel-
etal component of podocyte foot processes and is formed by
a unique assembly of linker and adaptor molecules.4 The
actin cytoskeleton determines proper podocyte foot process
structure and provides mechanical support for morphology
of glomerular podocytes. Moreover, its dynamic behavior
is necessary during podocyte development, in response to
injury, for counteraction of the forces that distend the
capillary wall and generally for podocyte foot process
flexibility. Notably, mutations/deletions in many podocyte
genes that result in foot process effacement (FPE) and
albuminuria ultimately impact cytoskeletal dynamics. Nor-
mally, the podocyte foot process cytoskeleton is organized as
highly ordered bundles of parallel actin filaments. When
effaced, however, the podocyte cytoskeleton is reorganized
and transformed into a dense network.5 Podocyte FPE is a
common ultrastructural finding in proteinuric diseases where
the shape of the foot process is widened and elongated;
however, the mechanisms are not yet well understood.
Cultured podocytes in vitro develop large lamellipodia, which
are adhesion and migration structures that may functionally
resemble podocyte processes in vivo. Lamellipodia are thin,
protrusive actin sheets giving rise to ruffles of the plasma
membrane at the leading edge of migrating cells or extending
cellular processes.6
We have identified over 300 glomerulus-upregulated genes
using expressed sequence tag profiling and microarray
analysis.7 Plekhh2, a previously uncharacterized gene, was
shown to be most strongly expressed by the testes and the
podocyte cells of the kidney glomerulus.8 It is a protein of
unique domain organization, having a coiled-coil segment
at the N terminus followed by two adjoined PH domains, a
MyTH domain and a FERM domain at the C terminus
(Figure 1a). Here we show that Plekhh2 expression is altered
in human FSGS, as well as in two mouse models of
glomerular nephropathy. In vitro studies of Plekhh2 sub-
cellular localization and interaction partners suggest that
Plekhh2 has a role in adhesion structures linking the
podocyte foot processes to the GBM. It may also contribute
to the connection of actin filaments to these structures and
affect the dynamics of the filaments. These findings therefore
reveal Plekhh2 as a novel, important component of the
podocyte foot processes.
RESULTS
Plekhh2 localizes to the podocyte foot processes and is
reduced in FSGS
Immunofluorescence and immunoelectron microscopy (iEM)
revealed that in the normal human glomerulus Plekhh2
localizes to the podocyte foot processes where it is mainly
found centrally in the foot process cytoplasm (56%) or close
to the plasma membrane (within a distance of 100 nm, 28%).
Some expression was also seen close to the GBM (12%) but
rarely in the slit diaphragm (4%; Figure 1b, c and e).
Analysis of renal biopsies from patients with perihilar and
tip lesion FSGS, which are the most common FSGS subtypes
in our patient population, indicated that there was a
significant reduction in total podocyte Plekhh2 expression
in perihilar FSGS compared with controls (0.7±0.2 vs.
1.8±0.5 Au/mm2; Figure 1f; all clinical data presented in
Supplementary Table S1 online). However, no correlation
between the degree of proteinuria, FPE (measured as slits/mm
GBM), and the amount of Plekhh2 (Au/mm2) was found.
Low labeling density for Plekhh2 was seen in areas of FPE
(Figure 1d) and a tendency toward decreased labeling was
also noted in areas without FPE (data not shown). In tip
lesion FSGS, we detected reduced levels of Plekhh2 in areas
with FPE. As mentioned above, a tendency toward decreased
labeling was seen in areas without FPE, but this was not
statistically significant. Intriguingly, a tendency for redis-
tribution of Plekhh2 from the plasma membrane to the
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Figure 1 |Plekhh2 localizes to podocyte foot processes and is
found in reduced levels in FSGS. (a) Schematic domain structure
prediction of Plekhh2 shows the presence of a putative a-helical
coiled-coil domain (CC), two adjoined PH domains, a MyTH
domain, and a FERM domain. Numbers indicate the location of
the domains in the mouse Plekhh2 polypeptide. (b) Plekhh2
localizes to podocyte foot processes giving ‘linear’ staining
in human glomerulus, as shown by immunofluorescence.
(c) Immunoelectron microscopy (iEM) analysis of Plekhh2 in the
normal glomerulus shows expression centrally in the cytoplasm of
the podocyte (P) foot processes (FP, arrowhead), in association
with the plasma membrane (arrowhead) or the GBM, but rarely
in the slit diaphragm (SD). No expression is detected in the
endothelial cells (E). (d) The labeling for Plekhh2 is reduced
in areas with FP effacement in the perihilar variant of focal
segmental glomerulosclerosis (FSGS). (e) Quantification of
Plekhh2 localization in the podocytes in control and patient
material. Bars represent the percentage of labeling observed in
the different compartments of the podocyte foot processes. SD, in
the slit diaphragm; membrane, membrane associated; cytoplasm,
centrally in the cytoplasm; GBM, adjacent to the glomerular
basement membrane. A tendency to redistribution of Plekhh2
from the plasma membrane centrally into the FP was seen in
FSGS. (f) Expression of Plekhh2 in human controls and biopsies,
based on semiquantitative iEM, expressed as the number
of gold particles/mm2 (Au/mm2). *Po0.05 compared with controls.
FPE, foot process effacement.
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central parts of the foot process was seen in both FSGS
subtypes, although this was statistically significant only in tip
lesion FSGS (Figure 1e). We have also examined renal
biopsies from patients with minimal change nephrotic
syndrome, membranous nephropathy, and diabetic nephrop-
athy, but found no significant change in the overall amount
of Plekhh2 in the podocytes, except for a reduction in areas
with FPE in minimal change nephrotic syndrome (data not
shown).
Plekhh2 localizes to the peripheral regions of lamellipodia in
cultured podocytes
To study the cellular function of Plekhh2, we turned our
attention to investigations of its subcellular localization.
When expressed heterologously as a Myc-tagged protein in
human podocytes, we found that Plekhh2 localized pre-
dominantly to the peripheral regions of lamellipodia (Figure
2a). Peripheral lamellipodia staining of Plekhh2 was similarly
observed in other cell types expressing the protein either
transiently or stably (Supplementary Figure S1 online).
Notably, this pattern of staining was confined to those
regions of individual subconfluent cells that did not
juxtapose neighboring cells, and no Plekhh2 staining of the
plasma membrane was otherwise noted in confluent cells that
abut against one another (Figure 2b). To exclude the
possibility that artificially high expression levels of Plekhh2
accounted for the observed lamellipodial expression, we
detergent-treated cells with 0.5% saponin before fixation and
immunostaining. This permeabilization strategy results in the
removal of the soluble pool of proteins while sparing those
that are more stably anchored. Under these conditions, we
found that Plekhh2 staining was partially retained, suggesting
association with detergent-insoluble cytoskeletal/membrane
structures (Supplementary Figure S2a and b online). In
addition, subcellular analysis of Plekhh2-expressing podo-
cytes indicated that Plekhh2 is present in the membrane,
cytoskeletal, and cytosolic (but not nuclear) fractions
(Supplementary Figure S2c online).
We also transiently transfected human podocytes with a
construct encoding green fluorescent protein (GFP)–Plekhh2
and followed the localization of the fusion protein in living
cells during their attachment, spreading, and migration on
fibronectin-coated surfaces. Plekhh2 was found in initial
adhesion structures present at the basal aspect of podocytes
very soon after cell plating (Supplementary Figure S3a/
Supplementary Video a and Figure S3b/Supplementary Video
b online). In spreading cells, GFP–Plekhh2 localized to
lamellipodia (Supplementary Figure S3d and f/Supplemen-
tary Videos d and f online), whereas in migrating podocytes
it was detected at the migration front (Supplementary Figure
S3c and e/Supplementary Videos c and e online). Supple-
mentary Figure S4 online shows that the construct encoding
for GFP–Plekhh2 gives a band of expected size on western
blot analysis (170 kDa).
To additionally assess the specificity of the observed
Plekhh2 localization, we turned our attention to the various
domains of Plekhh2. On the basis of comparative database
analysis, Plekhh2 is predicted to contain multiple putative
interactive domains including PH and FERM domains that
have previously been described as key determinants of
protein localization.9,10 In the following set of experiments,
we examined whether deletion of one or more of the
individual domains in the C-terminal half of Plekhh2 affected
its subcellular localization (Figure 3). Expression of a
truncation mutant lacking the entire C-terminal half (two
PH domains, MyTH domain, FERM domain) prevented
Plekhh2 lamellipodial expression, and resulted in its nuclear
accumulation. Conversely, expression of a Plekhh2 mutant
composed solely of its C-terminal half was targeted to the
lamellipodia. These studies demonstrate the importance of
the MyTH-FERM cassette and/or PH domains in targeting
Plekhh2 to lamellipodial structures. Both FERM and PH
domains, when singly expressed, demonstrated a propensity
to accumulate at lamellipodia. Deletion of either PH or
FERM domains of full-length Plekhh2 was not sufficient
to completely abolish Plekhh2 localization to lamellipodial
structures. This finding suggests that the PH and FERM domains
cooperate to ensure the proper localization of Plekhh2.
An analysis of the amino acid sequence of Plekhh2
indicated the presence of a PtdIns(3,4,5)P3 (PIP3) consensus
binding site in the PH1 domain (Figure 4a). To test the
significance of this finding, we mutated the selected conserved
residues (K711A and R722C, asterisk) and studied the
localization of the protein in podocytes. Although the K711A
mutation had no effect on Plekhh2 localization, the double
K711A/R722C mutation markedly affected the ‘linear’ lamelli-
podial localization of Plekhh2, particularly in the case of the
mutant lacking the FERM domain. The protein seemed to be
transported toward the cell periphery, but the staining was
very diffuse (Figure 4b). We also treated Plekhh2-expressing
MycPlekhh2/phalloidin
a
MycPlekhh2 MycPlekhh2
b
Figure 2 |Plekhh2 localizes to the peripheral region of
lamellipodia in cultured human podocytes. (a) Plekhh2
localizes near the lamellipodial plasma membrane in cells
spreading on fibronectin. Two cells are shown. (b) Plekhh2 does
not localize at the plasma membrane of cells grown to confluence
(left panel). Note that Plekhh2 accumulates at the plasma
membrane of a cell (left panel, boxed area) extending a
lamellipodial extrusion into an empty space (right panel, zoom).
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cells with wortmannin or LY294002, potent phosphatidyli-
nositol 3-kinase inhibitors. Both of these treatments
markedly reduced Plekhh2 localization to the plasma
membrane of lamellipodia (Figure 4c, Supplementary Figure
S5 online), with only about 25% of the Plekhh2 signal
remaining at this cellular location (Figure 4d). In contrast,
Plekhh2 variants composed either of only the PH domains
(PHPH) or lacking the FERM domain (DFERM) were
completely relocalized to the cytosol upon wortmannin or
LY294002 treatment (Supplementary Figure S5b and c
online). As predicted, localization of the DPHPH variant
was not altered by either of these two treatments. These
findings strongly suggest that interaction of the PH1 domain
with PIP3 contributes to Plekhh2 localization to the
peripheral regions of lamellipodia, and confirm that the
FERM domain at the C terminus of the polypeptide also
serves to target Plekhh2 to these sites.
Evidence that Plekhh2 associates with itself
The only recognizable domain within the N-terminal half of
the 1491-residue-long Plekhh2 polypeptide is a putative a-
helical coiled-coil domain located between amino acids 19 and
177 (Supplementary Figure S6a online). According to the
secondary structure prediction by the PSIPRED program,11
this segment folds into a continuous coiled-coil, except for one
short interruption (Supplementary Figure S6b online). Coiled-
coil domains are common oligomerization domains, the most
predominant oligomeric forms being dimers and trimers.
Analysis of the segment with the SCORER 2.0 program,12
which distinguishes parallel dimeric and trimeric coiled-coils,
predicts that the coiled-coil domain of Plekhh2 assembles into
a dimer. To provide experimental evidence for these predic-
tions, we tested by coimmunoprecipitation whether Plekhh2
self-associates. To this end, HEK293 cells were cotransfected
with full-length Plekhh2 tagged with either Myc or hemagglu-
tinin (HA) epitopes, followed by immunoprecipitation with
anti-HA antibodies and western blotting with those against the
Myc-tag. As shown in Figure 5a, these two full-length versions
of Plekhh2 associated with each other. As there is some
evidence from structural studies indicating that the FERM
domain is capable of forming dimeric structures,13 we tested
the involvement of this domain in Plekhh2 self-association.
However, no interaction was seen when HA-tagged full-length
Plekhh2 was coexpressed with the Myc-tagged FERM domain
(Supplementary Figure S7 online), indicating that association
does not occur through the FERM domain.
We also used fluorescent resonance energy transfer (FRET)
to confirm that Plekhh2 self-associates. In this experiment, we
coexpressed in human podocytes Plekhh2 proteins tagged at
their N termini with either GFP or Myc and measured the
change in GFP donor fluorescence following bleaching of the
red (Myc) acceptor fluorophore (Figure 5b). Under these
conditions, we detected a significant increase in the GFP signal
in lamellipodia of the transfected cells (Figure 5c). If the coiled-
coil domain located in the N terminus of Plekhh2 is indeed
biologically functional, we reasoned that full-length Plekhh2
may be able to alter the nuclear expression pattern of the
Plekhh2 mutant that lacks the entire C-terminal half, but that
still possesses its coiled-coil domain (the form DPHPHMyTH-
FERM). Immunofluorescent examination of cells coexpressing
these two proteins revealed that the truncated Plekhh2 partially
relocalized from the nucleus to the plasma membrane of
lamellipodia in the presence of the full-length protein (Figure
5d). Such a partial rescue of DPHPHMyTHFERM localization
to lamellipodia was not similarly observed in cells over-
expressing Ezrin. Altogether, these studies provide evidence
that the N-terminal half of Plekhh2, containing the coiled-coil
region, is sufficient for the self-association of Plekhh2, which
likely assembles into a dimer.
Plekhh2 interacts with Hic-5 and actin, and recruits Hic-5
from focal adhesions to the cell periphery
To predict the cellular function of Plekhh2, we used an
unbiased yeast two-hybrid approach for discovering protein
Plekhh2 full phalloidin Merge
ΔFERM phalloidin Merge
ΔMyTHFERM phalloidin Merge
ΔPHPHMyTH
FERM
phalloidin Merge
ΔPH1 phalloidin Merge
ΔPHPH phalloidin Merge
PHPH phalloidin Merge
FERM phalloidin Merge
PHPHMyTH
FERM
phalloidin Merge
PH PH MyTH FERM
FERM
PH PH
CC MyTH FERM
CC PH MyTH FERM
CC
CC PH PH
CC PH PH MyTH
CC PH PH MyTH FERM
Figure 3 | Localization of truncated Plekhh2 proteins in
transfected podocytes. A set of constructs in encoding
truncated versions of Plekhh2 and its isolated domains, all
containing the Myc-tag at the N terminus, were generated and
transfected into human podocytes. Cells were stained with anti-
Myc antibody. All Plekhh2 constructs partially directed the
expressed protein to the lamellipodial plasma membrane, except
for the version lacking the entire C-terminal half that localizes to
the nucleus. Deletion of either FERM or PHPH domains is not
sufficient to completely prevent Plekhh2 from localizing to
lamellipodia, indicating that both domains are important for its
peripheral localization. The dashed lines in the schematic
drawings indicate the regions of individual constructs that have
been deleted. Phalloidin staining used only to demark outer cell
borders. CC, coiled-coil domain.
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interactions, and screened a mouse kidney glomerular
complementary DNA (cDNA) library with full-length
Plekhh2 and its deletion variants. This screen identified
Hic-5, a paxillin-related focal adhesion protein (TGFB1i1),
and b-actin (ActB) as potential interacting partners of
Plekhh2 (Figure 6). Hic-5 was isolated in the screens with
full-length Plekhh2, the PHPHMyTHFERM form, and the
FERM domain as baits, whereas ActB was identified in the
screens with the latter two baits. These findings, which were
confirmed in a yeast-mating assay (Figure 6a, Supplementary
Figure S8 online), indicate that it is the FERM domain of
Plekhh2 that mediates interaction of Plekhh2 with these two
proteins. The interaction of Plekhh2 with Hic-5 was verified
in a coimmunoprecipitation assay using HEK293 cells
coexpressing HA-tagged Plekhh2 and Myc-tagged Hic-5
(Figure 6b, Supplementary Figure S7 online).
To assess the subcellular relationship between these two
proteins, we next examined their spatial distribution in
cultured human podocytes. In these cells, endogenous Hic-5
localizes mainly to focal adhesions (Figure 6c, Supplementary
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Figure 4 |PI3-K inhibition reduces lamellipodial localization of Plekhh2. (a) Alignment of the mouse Plekhh2 PH1 domain sequence
with sequences of various PtdIns(3,4,5)P3 (PIP3)-binding PH domains indicates that this domain of Plekhh2 contains the consensus
sequence for PIP3 binding. (b) The Plekhh2 PH1 domain–conserved residues K711 and R722 (marked with asterisk in panel a) were mutated
in the full-length or DFERM protein, and the proteins were localized in the podocytes by staining for the Myc-tag. Double mutation
markedly affected the ‘linear’ lamellipodial localization of Plekhh2, particularly in the case of the variant lacking the FERM domain. (c)
Treatment of full-length Plekhh2-expressing podocytes with wortmannin, a potent phosphatidylinositol 3 (PI3)-kinase inhibitor, results in a
reduction of Plekhh2 expression at the lamellipodia. (d) Quantification of the intensity of the Plekhh2 signal along the periphery of
lamellipodia (left images; white line, region of interest (ROI)) shows a decrease of about 75% following wortmannin treatment (n410 cells,
±s.e.m. for each treatment, RFU: relative fluorescence units). DMSO, dimethylsulfoxide.
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Figure S9a online). Following transfection of Plekhh2,
endogenous Hic-5 was found to partially relocalize to
lamellipodial extensions, a response that was observed as a
linear staining pattern located at the periphery of lamellipo-
dia, near the plasma membrane (Figure 6c, Supplementary
Figure S9b online). This was not due to overall changes in
Hic-5 expression (Supplementary Figure S9c online). Con-
sistent with the yeast two-hybrid results, such a relocalization
was also seen upon transfection of only the FERM domain of
Plekhh2, but not the DFERM form.
To examine the location of these two proteins in situ, we
analyzed human kidney samples by iEM (Figure 7a and b).
Hic-5 was occasionally found in the podocyte foot processes,
localized close to the GBM. Coimmunolabeling of Plekhh2
and Hic-5 with 10- and 5-nm gold particles, respectively,
indicated that there was significant colocalization of the two
proteins and that they are less than 20 nm apart from each
other, providing strong evidence that Plekhh2 and Hic-5
interact in vivo as well (Figure 7c and d). Glomerular
expression of both proteins was also verified by reverse
transcription-polymerase chain reaction (PCR; Supplemen-
tary Figure S9d online).
Plekhh2 stabilizes lamellipodial cortical actin by slowing
down actin depolymerization
Examination of peripheral Plekhh2 by confocal microscopy
indicated a significant overlap with the cortical actin
cytoskeleton both in the XY- and Z-scan (Figure 8a).
Together with the finding that ActB was isolated in the yeast
two-hybrid screen with the C-terminal half of Plekhh2, as
well as with its FERM domain, and the fact that Plekhh2 is
found in the cytoskeletal fraction of podocyte cell lysates, we
raised the question that Plekhh2 may regulate the dynamics
of the actin cytoskeleton at the cell cortex/lamellipodia. To
test this possibility, we compared the response of the actin
cytoskeleton to treatment with the actin monomer–seques-
tering drug latrunculin A in untransfected and Plekhh2-
transfected podocytes (Figure 8b, Supplementary Figure S10
online). In the absence of Plekhh2, latrunculin A treatment
resulted in a loss of parallel transversal stress fibers, as well as
of cortical actin filaments, with a concomitant appearance of
phalloidin-positive patches. However, in Plekhh2-expressing
cells treated with latrunculin A, actin expression was
preserved at the cortical region where it colocalized with
Plekhh2. The same response was not observed in cells
expressing DPHPHMyTHFERM, the truncated Plekhh2
mutant that localizes to the nucleus. In further studies
designed to assess the relationship between Plekhh2 and actin
dynamics, we examined whether polymerization or depoly-
merization of exogenous pyrene-labeled actin is differently
affected by lysates prepared from 293 cells stably expressing
Plekhh2 and control cells. Our results show that Plekhh2
overexpression contributed to stabilization of F-actin by
attenuating its depolymerization (Figure 8c).
Plekhh2, Hic-5, and actin show parallel changes in
glomerular gene expression in microarray profiles of mouse
glomerular disease models
Bioinformatic analysis of Plekhh2 and its associated proteins,
Hic-5 and actin, in glomerular microarray profiles from
lipopolysaccharide-induced nephrosis and db/db diabetic
nephropathy (Figure 9a) revealed that these genes exhibit a
coordinated change of expression: downregulation in the
lipopolysaccharide model of FPE and significant upregula-
tion in the Type II diabetes model. These analyses may
indicate that Plekhh2, Hic-5, and actin are collectively
involved in the origin and/or progression of podocyte injury
in mice, leading to proteinuria. The complex underlying
mechanisms accounting for this could be very different in
various human glomerular diseases and need to be studied
further.
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Figure 5 | The N-terminal half of Plekhh2 containing the
predicted coiled-coil domain mediates self-association of the
protein. (a) Full-length Plekhh2 tagged with either Myc or
hemagglutinin (HA) epitopes coimmunoprecipitate from lysates
of cotransfected HEK293 cells. (b, c) Green fluorescent protein
(GFP)–Plekhh2 signal intensity increases upon Alexa568 bleaching
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proteins (lower panel). As a positive control, we used GFP–Plekhh2
stained with anti-GFP- and Alexa Fluor 568–conjugated secondary
antibodies (upper panel). (d) Plekhh2 lacking its entire C-terminal
half (DPHPHMyTHFERM) is partially relocalized from the cell
nucleus to the cell periphery by coexpression of full-length
Plekhh2, but not by coexpression with Ezrin, a plasma membrane–
cytoskeleton linker protein. FRET, fluorescent resonance energy
transfer; IP, immunoprecipitation; WB, western blot.
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DISCUSSION
In this work, we investigated the function and subcellular
localization of Plekhh2, a recently identified scaffold-like
protein with high expression levels in the podocytes of the
kidney glomerulus. The results shed light on the role of the
various domains of Plekhh2, suggest a function for Plekhh2
in adhesion structures linking the podocytes to the under-
lying GBM, and implicate Plekhh2 as a protein involved in
the pathogenesis of kidney disease.
Plekhh2 is one of two previously uncharacterized Plekhh
proteins encoded in the mammalian genomes. A Plekhh
ortholog has also been described in Drosophila, Caenorhab-
ditis elegans, and zebrafish. In C. elegans, the loss of the
protein, termed MAX-1, was found to cause variable axon
guidance defects.14 It was also shown that a GFP–MAX-1
fusion protein was enriched in neuronal processes in a FERM
domain–dependent manner. The reasons for axon guidance
defects are not entirely clear, but MAX-1 may at least
HA   HA
a
c
pG
AD
T7
Ac
tB
H
ic
5
FERMPHPHMyTHFERMFull
– – –
+ + +
– + +
MycPlekhh2 Hic5 Merge
Ezrin Hic5 Merge
FERM Hic5 Merge
ΔFERM Hic5 Merge
b
M
yc
Hi
c5
M
yc
Hi
c5
+
H
AP
le
kh
h2
 
M
yc
Hi
c5
M
yc
Hi
c5
+
H
AP
le
kh
h2
WB:
anti-Hic5
50 kDa
Input
IP
Figure 6 |Plekhh2 interacts with Hic-5 and actin through its FERM domain and recruits Hic-5 to lamellipodia. (a) Yeast two-hybrid
screen of a mouse kidney glomerulus cDNA library indicates that Plekhh2 interacts via its FERM domain with Hic-5 and b-actin (ActB). Here,
the results were confirmed in a mating assay (þ , positive interaction; , no interaction). Note that ActB does not interact with full-length
Plekhh2, but only with the other two baits, the entire C-terminal half and the FERM domain. Hic-5 interacts with all three baits. These
findings indicate that the binding sites for Hic-5 and actin on the FERM domain are not identical. (b) Myc-tagged Hic-5 and HA-tagged
Plekhh2 coimmunoprecipitate from lysates of cotransfected HEK293 cells. (c) Expression of Plekhh2 causes partial relocalization of
endogenous Hic-5 from focal adhesions to lamellipodia (upper panel, arrowheads). The Plekhh2 FERM domain is also sufficient to induce
lamellipodial Hic-5 relocalization, whereas Plekhh2DFERM and Ezrin are without effect. HA, hemagglutinin; WB, western blot.
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contribute to the enrichment of a netrin receptor UNC-5 to
the growth cone. However, knockdown of the zebrafish MAX-1
was not found to cause apparent defects in neuronal axon
guidance, but instead cause defects in intersegmental vessel
patterning.15 Some evidence suggests that the protein might
be involved in mediating membrane localization of ephrin
proteins that may provide guidance cues for endothelial cell
migration.
It is also worth noting that the domain organization
within the C-terminal half of Plekhh2 resembles that in the
tail domains of several unconventional myosins, proteins
involved in various cellular functions.16 It is most similar to
myosin X, a protein shown to have a role in filopodia
elongation via PIP3 binding to one of its three PH domains,
as well as through interaction of its FERM domain with
integrins and other cargo that are transported to the
filopodial tips.16–19 The N-terminal head of myosin X is
composed of a motor domain, followed by a neck region
containing three IQ motifs and a coiled-coil region, of which
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the latter segment functions as a dimerization domain. In
the case of Plekhh2, secondary structure analysis indicates the
presence of a coiled-coil domain near the N terminus of the
polypeptide. The sequences of coiled coils are characterized
by a heptad repeat (a-b-c-d-e-f-g) comprising mostly hydro-
phobic residues at positions a and d. The minimum length
for the formation of stable coiled coils is reported to be three
heptad repeats or 21–23 residues.20,21 Plekhh2 is predicted to
contain an almost continuous 158-residue-long coiled coil.
Our results based on coimmunoprecipitation, FRET, and
other colocalization studies strongly suggest that this segment
is responsible for the self-association of the molecule.
It is well known that the basal cellular levels of PIP3 in
cells are low but significantly elevated upon phosphatidyli-
nositol 3-kinase activation by growth factors, such as platelet
derived growth factor and insulin. However, one has to keep
in mind that although overall PIP3 levels are low in the
absence of growth factor stimulation, the existing lipid is not
homogenously distributed throughout the plasma membrane
in polarized cells, but it is concentrated to the basolateral
membrane domain.22 This very likely reflects high basal levels
of phosphatidylinositol 3-kinase activity induced by receptors
such as integrins,23 and enrichment of the lipid phosphatase
PTEN, which converts PIP3 to PIP2, to the apical domain.24
In light of these facts, it is of considerable significance that
Plekhh2 localizes in situ to the foot processes, which anchor
the podocytes through integrins to the underlying basement
membrane. With regard to growth factors and PIP3 levels, it
is known that cell migration and adhesion is promoted by
platelet derived growth factor, a factor present in the serum.
In migrating cells, PIP3 accumulates at the leading edge,22 the
location where we can also find Plekhh2. Furthermore, it is of
particular interest to note that podocytes have been shown
to be sensitive to insulin.25 In their recent work, Welsh and
co-workers26 generated mice lacking the insulin receptor in
podocytes, and found that the mice develop significant
albuminuria with features such as effacement of the podocyte
foot processes and thickening of the GBM. Further studies
showed that both the mitogen-activated protein kinase and
PIP3-kinase signaling pathways in response to insulin were
abrogated. Moreover, insulin stimulation led to reorganiza-
tion of the actin cytoskeleton in cultured podocytes. On the
basis of our data indicating that PIP3 contributes to the
peripheral localization of Plekhh2, it is interesting to
speculate that Plekhh2 localization and function is under
the control of insulin signaling.
In transfected cells, we found that the FERM domain is
capable of targeting Plekhh2 to the cell periphery. In ERM
proteins, the FERM domain is involved in the binding of
PIP2,10,27 whose steady-state levels are much higher than
those of PIP3 (40-fold by one estimate28). The binding occurs
through a positively charged cleft between two of the
subdomains in the FERM domain. However, binding of
PIP2 is not a general feature of FERM domains, as that of
myosin X does not possess this positively charged cleft and
lacks the conserved PIP2-interactive residues.29 Moreover,
considering the Plekhh2 FERM domain and possible PIP2
binding, one has to bear in mind that PIP2 is primarily
enriched at the apical membrane domain in polarized
epithelial cells.24 Nevertheless, we show in this study that
Plekhh2 directly interacts with actin through its FERM
domain, suggesting that this domain contributes to Plekhh2
peripheral localization by interacting with the cortical actin
cytoskeleton. The observed molecular interaction between
the Plekhh2 FERM domain and actin is a novel finding and
places Plekhh2 among a limited class of FERM domain–con-
taining proteins that have been shown to possess this
capability (merlin,30,31 myosin VII,32,33 and talin34). Note
that in all these cases the interaction was shown in a
cosedimentation assay, whereas here we use an unbiased
approach. The affinity for the interaction was not measured
in case of all these proteins, but when measured the results
indicate that it is low. Even if this were the case for Plekhh2, it
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is possible that the actin concentration at the cell cortex is
high enough for the interaction of Plekhh2 with the cortical
actin cytoskeleton. Our results obtained using latrunculin A
suggest that the Plekhh2–actin interaction appears to protect
the cortical actin cytoskeleton by slowing down its depoly-
merization.
Our findings show that Plekhh2 interacts through its
FERM domain not only with actin but also with Hic-5,
a transforming growth factorb1-induced paxillin homolog
that localizes to focal adhesions in cultured podocytes.
Importantly, Plekhh2 and Hic-5 were also found to colocalize
in vivo. Hic-5 has been implicated in integrin-mediated
signaling by shuttling between the nucleus and focal
adhesions.35 There is also evidence of its function in cell
migration,36,37 adhesion,38 and epithelial cell differentia-
tion.39 Of significant interest for our study, Hic-5 has been
shown to interact with the PINCH-integrin-linked kinase-
a–parvin complex, which has a critical role in the control of
podocyte adhesion and morphology.40–43 Thus, it appears
that, at the sole of foot processes, Plekhh2 is, very likely in the
form of a dimer, part of a multiprotein adhesion complex,
where it may be involved in linking the complex to the
plasma membrane. Plekhh2 may also contribute to the
connection of the complex to actin filaments, and even
contribute to regulation of their dynamics (Figure 9b). With
that said, it is of interest to note that in the lipopolysacchar-
ide-induced proteinuria mouse model that is also associated
with transient podocyte FPE, glomerular Plekhh2, Hic-5, and
actin expression is concomitantly downregulated.44 Further-
more, there is some evidence from a genome-wide associa-
tion study that sequence variants in the Plekhh2 gene region
may be associated with diabetic nephropathy, a complication
characterized by features such as flattening of the podocyte
foot processes and thickening of the GBM.45 Other data
shown here, using semiquantitative iEM, indicate a reduced
Plekhh2 expression and relocalization in FSGS. It is already
known that genetic mutations associated with the hereditary
form of FSGS, such as a-actinin 4,46 CD2AP,47 and
TRPC6,48,49 affect the structure of podocyte cytoskeleton by
impairing actin cytoskeleton dynamics.
Finally, recent structural studies demonstrate that the
MyTH and FERM domains interact with one another,
forming a functional and structural supramodule.29,50,51 It
remains to be seen whether the MyTH domain of Plekhh2
has FERM domain–independent functions. This appears to
be the case in myosin X, where it directly binds to tubulin
through a positively charged surface patch.29 It is also worth
pointing out that whereas Hic-5 interacted with full-length
Plekkh2, the C-terminal half, and the FERM domain in our
yeast assays, ActB bound the latter two baits only. These
findings indicate that the binding sites of Hic-5 and actin on
the FERM domain are not identical, and also that the actin-
binding site is hidden in full-length Plekhh2. Thus, it seems
that Plekhh2 can exist in at least two conformational states,
as is the case for the ERM proteins10 and several of the
unconventional myosins (ref. 18, and references therein).
MATERIALS AND METHODS
Human patients and material
Normal renal tissue was taken from unaffected kidneys surgically
removed because of localized carcinoma. Patients who fulfilled the
criteria for FSGS clinically and histopathologically were chosen for
the study. Biopsies were taken for diagnostic purposes and re-
examined to confirm the diagnosis. Biopsy material has been saved
prospectively and embedded in a low-temperature resin allowing
iEM. The number of cases is thus limited. All materials were used in
agreement with the local Board of Ethics.
Expression constructs
Expression constructs were generated by cloning of PCR-amplified
fragments into various expression vectors using established
molecular biological methods. Inserts were amplified from kidney
cDNA (Mouse MTC Panel I, Clontech Laboratories, Palo Alto, CA)
with Long PCR Enzyme Mix (Fermentas International, Burlington,
Canada), and sequenced to confirm the absence of PCR-generated
mutations. The PCR program used was as follows: 1 cycle of 951C/
4min, 30 cycles of 951C/1min, 511C/1min, 721C/2–10min, and 1
cycle of 721C/10min. For yeast two-hybrid screening, inserts were
cloned into the vector pGBKT7 (Clontech Laboratories) in frame
with the Gal4 DNA-binding domain. For expression in mammalian
cells, cDNAs were cloned into pcDNA3.1 (Invitrogen, Carlsbad,
CA), or vectors with various N-terminal tags (pCMV-Myc, pCMV-
HA, or pEGFP-C; all from Clontech Laboratories).
Antibodies
The following commercial primary antibodies were used: rabbit
anti-Plekhh2 (Sigma Prestige Antibodies, St Louis, MO, AV53218),
mouse anti-Hic5 (BD Transduction Labs, San Jose, CA, 611164),
mouse anti-c-Myc (Sigma, M4439), rabbit anti-Myc (Sigma,
C3956), mouse anti-HA (Sigma, H6908), rabbit anti-GFP (Invitro-
gen Molecular Probes, A11122), mouse anti-ezrin (Invitrogen,
35-7300), rabbit anti-lamin A/C (Cell Signaling, Beverly, MA, 2032),
anti-calnexin (Abcam, Cambridge, UK), rabbit anti-actin-b
(Abcam), and anti-ERK (Cell Signaling). All mouse antibodies
were monoclonal. Proteins were visualized with secondary anti-
bodies conjugated to various Alexa Fluor dyes (488, 546, 568; all
from Invitrogen) or horseradish peroxidase (GE Healthcare, Piscat-
away, NJ).
Transient and stable transfections
Human podocytes were grown at 331C/5% CO2 in RPMI
supplemented with 10% fetal bovine serum (Invitrogen), 1
insulin–transferrin–selenium-A supplement (Invitrogen), and anti-
biotics (100U/ml penicillin and 100 mg/ml streptomycin; Invitro-
gen), as previously described.52 HEK293, COS7, and CHO cells were
cultured at 371C/5% CO2 in Dulbecco’s modified Eagle’s medium
containing the same supplements, except insulin-transferrin-sele-
nium-A. Cells were transiently transfected with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s recommendations. For
generation of stable GFP–Plekhh2-expressing HEK293cell clones,
cells were selected and maintained in medium containing 500 mg/ml
of G418. Stable transfectants were characterized by immunofluor-
escence and western blotting for GFP–Plekhh2 expression.
Immunofluorescence
For immunofluorescence, cells were grown on fibronectin-coated
glass coverslips. For coating, coverslips were incubated with
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10 mg/ml of fibronectin (Invitrogen, 33010-018) for 2 h at room
temperature, followed by several washes with phosphate-buffered
saline (PBS). Cells were fixed with 4% paraformaldehyde solution
for 20min at room temperature, after which they were permeabi-
lized by incubation with 0.1% Triton X-100/PBS for 5min, followed
by an incubation with 2% bovine serum albumin/PBS (blocking
solution) for 1 h. In some experiments, cells were treated with 0.5%
saponin/PBS for 20min before fixation. After blocking, cells were
incubated with primary antibodies for 1 h at room temperature,
washed several times with PBS, and then incubated for 1 h with a
suitable secondary antibody. All antibodies were diluted in the
blocking solution. Secondary antibody solutions also contained
rhodamine–phalloidin and 4,6-diamidino-2-phenylindole to stain
F-actin and cell nuclei, respectively. For double labeling, incubations
were performed sequentially to prevent cross-reactions. Photos were
taken using Zeiss LSM510 confocal microscope, with  20,  40, or
 63 objectives.
Drug treatments
Transiently transfected human podocytes were plated on fibro-
nectin-coated coverslips in 24-well plates, and left to adhere and
spread for 16 h. Thereafter, cells were incubated for 1 h at 371C
with 100 nmol/l of wortmannin (Sigma, W1628) or 50 mmol/l
LY294002 (Cell Signaling, 9901), inhibitors of phosphatidylino-
sitol 3-kinase, or 10 mg/ml of the actin monomer–sequestering
drug latrunculin A (Sigma, L5163), all diluted from stock
solutions prepared in dimethylsulfoxide. Control cells were
incubated with the vehicle only. After the incubation, cells were
fixed and stained for Myc-tagged Plekhh2 and F-actin as described
above.
Western blotting, coimmunoprecipitations, and subcellular
fractionations
Western blotting was carried out following standard procedures. For
coimmunoprecipitations, confluent transiently transfected HEK293
cells were washed twice in cold PBS and lysed in 0.5% Triton X-100,
20mmol/l Tris-HCl (pH 7.4), and 150mmol/l NaCl buffer contain-
ing protease inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany) and phosphatase inhibitors (1mmol/l NaVO3, 50mmol/l
NaF). Lysates were clarified by centrifugation (14,000 g), incubated
with primary antibodies overnight, followed by incubation with
protein AþG agarose beads (Roche Diagnostics) for 1 h at 41C.
Thereafter, the beads were washed three times with the lysis buffer,
resuspended in 1 SDS-sample loading buffer, and boiled for
10min. Eluted proteins were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and western blotting. For
subcellular fractionation, cell lysates were fractionated with the
Qproteome Cell Compartment Kit (Qiagen, Valencia, CA) before
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
western blotting.
Fluorescent resonance energy transfer in fixed cells
A detailed description of the FRET technique can be found
elsewhere.53 We utilized this method to confirm dimerization of
the Plekhh2 protein using human podocytes cotransfected with
GFP- and Myc-tagged versions of Plekhh2. The Fo¨rster constant, R0,
for the donor–acceptor pair used in this study, Alexa488 and
Alexa568, is 62 A˚. To determine FRET, we quantified the quenching
of donor fluorescence by performing acceptor photobleaching.
FRET measurements were recorded using a Zeiss LSM510 inverted
confocal microscope, apochromat  63/1.4 numerical aperture oil
immersion objective, and the Zeiss LSM510 software version 2.8.
Briefly, fluorophores were excited with 488- and 543-nm lasers and
images collected separately. The acceptor, Alexa568, was then
irreversibly photobleached in a selected adequate region by
continuous excitation with a 543-nm laser for about 30 s. Thereafter,
residual Alexa568 and Alexa488 images were obtained under the
same settings as prebleach images, and identical regions on
individual cells were outlined in the photobleached area and
processed using ImageJ. Ratios between Alexa488 intensities of
the selected region, after and before photobleaching, were
calculated to quantify FRET. In a typical experiment, 15–20 cells
were measured for each sample. As a positive control for FRET,
we examined GFP–Plekhh2-expressing cells immunostained for
the GFP using Alexa568–labeled immunoglobin-G as a secondary
antibody.
Yeast two-hybrid screening
For yeast two-hybrid screening, we used a mouse kidney glomerulus
cDNA library custom-generated by Clontech Laboratories. The
library was screened with baits encoding the Gal4 DNA-binding
domain fused to full-length Plekhh2 or its deletion variants.
Screening was carried out by yeast mating according to the
manufacturer’s instructions. Diploids were selected through several
rounds of culture on minimal synthetic dropout medium. Plasmids
from obtained colonies were isolated, sequenced, and analyzed with
the BLAST algorithm at the National Center for Biotechnology
Information. Additional confirmation of interactions was obtained
by performing mating of the yeast Y187 and AH109 strains carrying,
respectively, a bait and a prey.
Immunoelectron microscopy
Samples from human renal cortexes were fixed in 3% paraformal-
dehyde in 0.1mol/l phosphate buffer. After fixation, samples were
cut into smaller pieces and dehydrated by stepwise increased
concentration of methanol, and in each step gradually lowering the
temperature down to 401C in a Leica EMAFS (Leica Microsystem,
Wien, Austria) and embedded and polymerized in Lowicryl K11M
(Polysciences, Warrington, PA) at 401C. Ultrathin sections were
cut at room temperature and placed on carbon formvar-coated
nickel grids. IEM was performed as described elsewhere,54 with
Plekhh2 and Hic-5 labeled with 10- and 5-nm gold particles,
respectively. For semiquantification by iEM, six locations per
glomerulus (1–2 glomeruli, depending on material) were system-
atically chosen with a random start at low magnification along the
glomerular capillaries. Three images were taken from each location,
including areas with or without FPE (no sclerotic areas), giving a
minimum of 18 images/specimen for semiquantification. Prints at a
final magnification of  52,000 were examined and the number of
gold markers (Au) was counted. The area of the corresponding
compartment was calculated by point counting, using a 1 1 cm
square lattice, and expressed as mm2. The concentration of Plekhh2
was expressed as the number of gold particles per square micrometer
(Au/mm2). The GBM length and the number of slits were expressed
as a ratio slits/mm to evaluate FPE (o1 slit/mm GBM defined as
FPE). Statistical analysis: in comparisons between groups, a one-way
analysis of variance was used followed by Dunnett’s test comparing
the diseased group means with the control group mean. The
Spearman rank-order correlation coefficient was used to measure
the association between variables within each group. Po0.05 was
considered statistically significant.
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In vitro actin polymerization and depolymerization assays
In vitro actin polymerization and depolymerization assays using the
Actin Polymerization Kit (Biochem, Denver, CO; BK003) were used
to study the role of Plekhh2 in the actin assembly processes. The
assay relies on the difference between fluorescent signals of pyrene-
labeled monomeric G-actin and polymerized pyrene/F-actin (used
as positive controls in our experiments). For these assays, we used
lysates prepared from 293 cells stably expressing GFP–Plekhh2, and
control cells. Cells were plated onto plates coated with 10 mg/ml of
fibronectin, and allowed to adhere overnight in a serum-free media,
followed by an overnight treatment with medium containing 10%
fetal calf serum or 30 mg/ml of platelet derived growth factor BB
(Invitrogen, PHG0044). After this, cells were collected and lysed for
3 h at 41C in a buffer containing 20mmol/l Tris-HCl, pH 7.5,
20mmol/l NaCl, and protease inhibitors. Lysates were clarified by
centrifugation at 14,000 r.p.m. for 10min. The actin polymerization
and depolymerization assays were performed according to the
manufacturer’s instructions, and fluorescence kinetic measurements
were recorded with TECAN GENiosPro.
Live-cell imaging
Imaging of GFP–Plekhh2-expressing human podocytes plated on
fibronectin-coated glass coverslips was started immediately after cell
plating. Imaging was continued overnight, with images being taken
every 5min (Zeiss LSM 510 microscope,  40 objective). They were
then processed into a movie with the ImageJ program.
Gene expression profiling with Affymetrix
Two mouse glomerular disease models were included in this
analysis: lipopolysaccharide-induced nephrosis44 and Type II
diabetes (db/db) (Norlin J, He L, Tryggvason K, Betsholtz C,
manuscript in preparation). The mouse glomerular RNA was
isolated and hybridized on Affymetrix arrays, respectively, and the
array data were processed as previously described.55 These data were
used for comparative analyses in this study.
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Video b. Localization of Myc-Plekhh2 in fixed podocytes.
Video c. Localization of GFP–Plekhh2 during cell migration.
Video d. Localization of GFP–Plekhh2 during cell spreading.
Video e. Localization of GFP–Plekhh2 during cell migration.
Video f. Localization of GFP–Plekhh2 during cell spreading.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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